Saturday, October 31, 2026

Salesforce Stock Over 3% Down On Wednesday

ViaNews Editorial Team

December 9, 2020

Salesforce Stock Over 3% Down On Wednesday
Shares of Salesforce fell 3.23% to $220.49 at 16:34 EST on Wednesday, after four successive sessions in a row of gains. The New York Stock Exchange is falling 0.39% to $14,346.60, following yesterday's upward trend, on what up to now seems, a somewhat rough trend exchanging session today. Salesforce's last close was $227.86, 29.03% under its 52-week high of $284.50.

Salesforce's Sales

Salesforce's sales growth is 17% for the ongoing quarter and 17.9% for the next. The company's growth estimates for the present quarter and the next is 13.6% and 8.6%, respectively.

Salesforce's Revenue

Year-on-year quarterly revenue growth grew by 20.1%, now sitting on 20.29B for the twelve trailing months.

Salesforce's Stock Top and Bottom Yearly Value

Salesforce's stock is valued at $220.49 at 16:34 EST, way under its 52-week high of $284.50 and way above its 52-week low of $115.29.

Salesforce's Moving Average

Salesforce's worth is way below its 50-day moving average of $246.30 and under its 200-day moving average of $222.25.

Previous days news about Salesforce

According to Business Insider on Sun Dec 6, "Salesforce has seen some significant executive upheaval in 2020, including the departure of two of Marc Benioff's C-suite executives. Former co-CEO Keith Block stepped down from his role after less than two years on the job in February and, more recently, chief financial officer Mark Hawkins announced plans to leave the company at the end of January, to be replaced by current chief legal officer Amy Weaver.  "
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com